Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol. 2022 05; 81(5):515-522.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Carcinoma, Transitional Cell
Fatigue
Female
Humans
Male
Pain
Platinum
Programmed Cell Death 1 Receptor
Quality of Life
Urinary Bladder Neoplasms

authors with profiles

Peter O'Donnell